Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 5;3(4):dlab157.
doi: 10.1093/jacamr/dlab157. eCollection 2021 Dec.

Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis

Weiping Ling  1 , Luis Furuya-Kanamori  1 , Yukiko Ezure  1 , Patrick N A Harris  1   2 , David L Paterson  1
Affiliations
Review

Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis

Weiping Ling et al. JAC Antimicrob Resist. .

Abstract

Background: Carbapenem-resistant Acinetobacter (CRA) infections have been associated with increased morbidity and mortality in hospitalized patients. This systematic review and meta-analysis aimed to quantify the association between CRA infections and adverse clinical outcomes.

Methods: Three databases (i.e. PubMed, EMBASE and Scopus) were searched for epidemiological studies that compared mortality, severe sepsis or shock, or bacteraemia among adult inpatients with CRA infections and those with carbapenem-susceptible Acinetobacter (CSA) infections. The pooled ORs for the three outcomes were estimated using the inverse variance heterogeneity model.

Results: Thirty-four studies were included. Patients with CRA infections had higher odds of mortality (31 studies, OR = 2.10, 95% CI: 1.58-2.79, I 2=60.6%) and severe sepsis or septic shock (7 studies, OR = 1.51, 95% CI: 1.09-2.09, I 2=0%) compared with CSA-infected patients. There was no difference in the odds of bacteraemia (four studies, OR = 1.39, 95% CI: 0.79-2.46, I 2=38.1%). CRA-infected patients presented with worse comorbidity at admission (e.g. APACHE score) (eight studies, standardized mean difference = 0.25, 95% CI: -0.01 to 0.52) and had lower frequency of appropriate antibiotic therapy. Results were consistent when pooling 16 study-adjusted risk estimates for mortality. There was no difference in risk of mortality from CRA infection when compared across geographical regions, country income, median year of enrolment and day of mortality from infection onset.

Conclusions: CRA-infected patients had worse clinical outcomes. This might be due to delay in appropriate antibiotic therapy, patients being sicker at admission and CRA strains potentially being more virulent than CSA strains. Improving appropriateness of antibiotic therapy in CRA-infected patients could reduce adverse clinical outcomes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA diagram for study inclusion and exclusion.
Figure 2.
Figure 2.
Forest plot of 31 studies estimating the association between CRA infection and all-cause mortality. Weights are from Doi’s IVHet model.
Figure 3.
Figure 3.
Forest plot of seven studies estimating the association between CRA infection and severe sepsis or septic shock. Weights are from Doi’s IVHet model.
Figure 4.
Figure 4.
Forest plot of four studies estimating the association between CRA infection and bacteraemia. Weights are from Doi’s IVHet model.
See this image and copyright information in PMC

References

    1. Fournier PE, Richet H.. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: 692–9. - PubMed
    1. Corbella X, Montero A, Pujol M. et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38: 4086–95. - PMC - PubMed
    1. Lolans K, Rice TW, Munoz-Price LS. et al. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50: 2941–5. - PMC - PubMed
    1. CDC. Antibiotic Resistance Threats in the United States. 2019. 10.15620/cdc:82532. - DOI
    1. Peleg AY, Seifert H, Paterson DL.. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538–82. - PMC - PubMed

LinkOut - more resources